Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $0.84 and traded as high as $0.9431. Brainstorm Cell Therapeutics shares last traded at $0.9088, with a volume of 78,591 shares traded.
Brainstorm Cell Therapeutics Trading Down 5.4%
The company’s 50-day simple moving average is $0.95 and its 200-day simple moving average is $0.84. The stock has a market capitalization of $12.26 million, a price-to-earnings ratio of -0.26 and a beta of 0.28.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). On average, equities research analysts expect that Brainstorm Cell Therapeutics Inc. will post -3.01 earnings per share for the current fiscal year.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc is a biotechnology company focused on developing cell-based therapies for neurodegenerative diseases. The company’s technology platform uses autologous mesenchymal stem cells, derived from a patient’s bone marrow and induced to produce neurotrophic factors that may support nerve-cell survival and repair.
Its lead product candidate, NurOwn, also known as debamestrocel or MSC-NTF cells, is being developed primarily for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis.
Featured Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
